Cigarette smoke and pro-inflammatory cytokines are directly linked to the initiation, progression, and metastasis of lung cancer. We have shown that primary cigarette smoke, nicotine, and the tobacco carcinogen NNK as well as the cytokine TNF suppress the metastasis suppressor gene BRMS1 which we have shown to inhibit metastasis in lung cancer. The purpose of this proposal is to characterize and better understand the regulation of BRMS1 at an epigenetic and post-translational level in lung cancer. Given that the majority of lung cancer patients present with metastatic disease and that it remains the number one cancer killer in the world, understanding how BRMS1 is regulated both transcriptionally and through post-translational modifications is important. Experiments described in Aim I of this proposal will investigate how the transcription factor NF-kB regulates methylation and transcriptional silencing of the BRMS1 promoter. Specifically, RelA/65, the transcriptionally active subunit of NF-kB, binds to BRMS1 DNA and promotes DNA and histone methyltransferases recruitment to chromatin which transcriptionally silences BRMS1. The goal of this aim is determine the mechanisms through which RelA/p65 regulates BRMS1 transcription and to extend these observations using human lung cancer specimens. In addition to transcriptional regulation of BRMS1, TNF, nicotine and NNK enhance casein kinase II mediated post-translational modifications of BRMS1 protein, including phosphorylation and ubiquitination which target BRMS1 to the proteasome. Experiments in Aim II of the proposal will identify specific casein kinase II phosphorylation residues in BRMS1 and what effect mutation(s) of these sites have on BRMS1 nuclear exportation and subsequent ubiquitination and proteasome- mediated degradation. Other experiments will map specific lysine residues that are ubiquitinated using mass spectroscopy and what effect mutations of these functionally relevant lysine residue(s) have on BRMS1 protein expression. Experiments proposed in Aim III use an inducible Cre/lox-P system lung cancer metastasis mouse model to explore the specific and separate contribution(s) of transcriptional and casein-kinase II mediated post- translational modifications of BRMS1 to the development of metastases. Collectively, experiments outlined in this proposal will elucidate the mechanisms through which BRMS1 is independently regulated at the chromatin level and through post-translational modifications. Our observations that BRMS1 is regulated by these two mechanisms and that its suppression can occur independent of selected inhibition of one mechanism has significant translational potential and speaks directly to the putative clinical cancer relevance and the significance of the project.

Public Health Relevance

Lung cancer is the number one cancer killer in the United States and most people present withadvanced stage or metastatic disease. Our research is focused on understanding how a specificprotein called BRMS1 helps regulate lung cancer metastases. The overall goal of this researchis to improve our understanding of how lung cancer spreads; which ultimately is necessary inorder to design novel targeted therapies for this deadly disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA136705-06
Application #
8730432
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Ault, Grace S
Project Start
2009-07-01
Project End
2014-05-31
Budget Start
2014-01-21
Budget End
2014-05-31
Support Year
Fiscal Year
2014
Total Cost
$204,508
Indirect Cost
$64,601
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Wamsley, J Jacob; Kumar, Manish; Allison, David F et al. (2015) Activin upregulation by NF-?B is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer. Cancer Res 75:426-35
Eguchi, Takashi; Kadota, Kyuichi; Park, Bernard J et al. (2014) The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210-22
Adusumilli, Prasad S; Cherkassky, Leonid; Villena-Vargas, Jonathan et al. (2014) Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6:261ra151
Hall, Emily H; Liu, Yuan; Xiao, Aizhen et al. (2014) Inhibition of breast cancer metastasis suppressor 1 promotes a mesenchymal phenotype in lung epithelial cells that express oncogenic K-RasV12 and loss of p53. PLoS One 9:e95869
Liu, Yuan; Mayo, Marty W; Nagji, Alykhan S et al. (2013) BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300. Cancer Res 73:1308-17
Kumar, Manish; Allison, David F; Baranova, Natalya N et al. (2013) NF-*B regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells. PLoS One 8:e68597
Liu, Y; Mayo, M W; Nagji, A S et al. (2012) Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1. Oncogene 31:1143-54
Zhao, Yunge; Sharma, Ashish K; LaPar, Damien J et al. (2011) Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation. Am J Physiol Lung Cell Mol Physiol 300:L718-29
Nagji, Alykhan S; Liu, Yuan; Stelow, Edward B et al. (2010) BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer. J Pathol 221:229-37
Nagji, Alykhan S; Cho, Sang-Hoon; Liu, Yuan et al. (2010) Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol Cancer Ther 9:2834-43

Showing the most recent 10 out of 11 publications